HS-20093

The FDA granted Breakthrough Therapy Designation to GSK'227 for relapsed or refractory osteosarcoma after two prior lines of therapy.

HS-20093/GSK'227, a B7-H3-targeted ADC, has been granted FDA Breakthrough Therapy Designation for relapsed or refractory osteosarcoma after two prior lines of therapy.

Hansoh Pharmaceutical's HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3, has received Breakthrough Therapy designation from both the NMPA and the US FDA.

Jiangsu Hansoh's HS-20093, a B7-H3-targeted ADC, has received Breakthrough Therapy Designation from China's NMPA for extensive-stage small cell lung cancer (ES-SCLC) following first-line treatment.

Hansoh Pharmaceutical's HS-20093, a B7-H3-targeted antibody-drug conjugate (ADC), has received Breakthrough Therapy Designation from China's NMPA.